The findings of "conversion to positive" in cells of recurrent cervical tumors showed by us and other authors [25,31] strongly suggest that expression of HER2 may have a role in tumor resistance and progression as shown in experimental models, and therefore its targeting in recurrent cervical cancer could have therapeutic value. This evidence concerns the gene ERBB2 and neoplasm.